1. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. American family physician. 2000;61(10):3090–6. [PubMed] [Google Scholar]
2. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. The journal of sexual medicine. 2009;6(8):2133–42. [PubMed] [Google Scholar]
3. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.. [Climacteric : the journal of the International Menopause Society Research Support, Non-U.S. Gov’t]. 2016;19(2):188–97. [PMC free article] [PubMed] [Google Scholar]
4. Moral E, Delgado JL, Carmona F, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric : the journal of the International Menopause Society. 2018;21(2):167–73. [PubMed] [Google Scholar]
5. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Maturitas. [Consensus Development Conference Research Support, Non-U.S. Gov’t]. 2014;79(3):349–54. [PubMed] [Google Scholar]
6. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902; quiz 3–4. [PubMed] [Google Scholar]
7. DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe. J Womens Health (Larchmt). [Comparative Study]. 2015;24(9):713–22. [PubMed] [Google Scholar]
8. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric : the journal of the International Menopause Society. [Review]. 2014;17(1):3–9. [PubMed] [Google Scholar]
9. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstetrics and gynecology. [Practice Guideline]. 2014;123(1):202–16. [PubMed] [Google Scholar]
10. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53. [PubMed] [Google Scholar]
11. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. [Practice Guideline Research Support, Non-U.S. Gov’t]. 2015;100(11):3975–4011. [PubMed] [Google Scholar]
12. Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstetrics and gynecology. [Review]. 2014;124(6):1147–56. [PMC free article] [PubMed] [Google Scholar]
13. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstetrics and gynecology. [Meta-Analysis Research Support, Non-U.S. Gov’t]. 1998;92(4 Pt 2):722–7. [PubMed] [Google Scholar]
14. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane database of systematic reviews. [Meta-Analysis Research Support, Non-U.S. Gov’t Review]. 2016(8):CD001500. [Google Scholar]
15. Mitchell CM, Reed SD, Diem S, et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA internal medicine. 2018;178(5):681–90. [PMC free article] [PubMed] [Google Scholar]
16. Pinkerton JV, Kaunitz AM, Manson JE. Not time to abandon use of local vaginal hormone therapies. Menopause. 2018;25(8):855–8. [PubMed] [Google Scholar]
17. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women’s EMPOWER Survey: Identifying Women’s Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. The journal of sexual medicine. 2017;14(3):413–24. [PubMed] [Google Scholar]
18. Manson JE, Goldstein SR, Kagan R, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause. [Editorial]. 2014;21(9):911–6. [PubMed] [Google Scholar]
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.]. 2002;288(3):321–33. [PubMed] [Google Scholar]
20. Archer DF . Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause. [Research Support, Non-U.S. Gov’t Review]. 2010;17(1):194–203. [PubMed] [Google Scholar]
21. Vulvar Lev-Sagie A. and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations. Clinical obstetrics and gynecology. [Review]. 2015;58(3):476–91. [PubMed] [Google Scholar]
22. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. American journal of obstetrics and gynecology. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2002;186(5):944–7. [PubMed] [Google Scholar]
23. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric : the journal of the International Menopause Society. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2005;8(1):83–92. [PubMed] [Google Scholar]
24. Dorr MB, Nelson AL, Mayer PR, et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertility and sterility. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2010;94(6):2365–8. [PubMed] [Google Scholar]
25. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric : the journal of the International Menopause Society. [Randomized Controlled Trial]. 2010;13(3):219–27. [PubMed] [Google Scholar]
26. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. [Clinical Trial]. 2002;9(3):179–87. [PubMed] [Google Scholar]
27. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20. [PMC free article] [PubMed] [Google Scholar]
28. Morch LS, Kjaer SK, Keiding N, Lokkegaard E, Lidegaard O. The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study. International journal of cancer. [Research Support, Non-U.S. Gov’t]. 2016;138(6):1506–15. [PubMed] [Google Scholar]
29. Lokkegaard E, Nielsen LH, Keiding N. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke. 2017;48(8):2266–9. [PubMed] [Google Scholar]
30. Carrasquilla GD, Frumento P, Berglund A, et al. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies. PLoS medicine. [Observational Study]. 2017;14(11):e1002445. [PMC free article] [PubMed] [Google Scholar]
31. Belanger C, Speizer FE, Hennekens CH, Rosner B, Willett W, Bain C. The nurses’ health study: current findings. The American journal of nursing. [Research Support, U.S. Gov’t, P.H.S.]. 1980;80(7):1333. [PubMed] [Google Scholar]
32. Belanger CF, Hennekens CH, Rosner B, Speizer FE. The nurses’ health study. The American journal of nursing. 1978;78(6):1039–40. [PubMed] [Google Scholar]
33. Colditz GA, Manson JE, Hankinson SE. The Nurses’ Health Study: 20-year contribution to the understanding of health among women. Journal of women’s health / the official publication of the Society for the Advancement of Women’s Health Research. [Research Support, U.S. Gov’t, P.H.S.]. 1997;6(1):49–62. [Google Scholar]
34. Bao Y, Bertoia ML, Lenart EB, et al. Origin, Methods, and Evolution of the Three Nurses’ Health Studies. American journal of public health. 2016;106(9):1573–81. [PMC free article] [PubMed] [Google Scholar]
35. World Health Organization; IHD Registers: Report of the Fifth Working Group. . In: Organization WH, editor. Copenhagen; 1971. [Google Scholar]
36. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology. [Guideline Practice Guideline]. 2000;36(3):959–69. [PubMed] [Google Scholar]
37. Walker AE, Robins M, Weinfeld FD. The National Survey of Stroke. Clinical findings. Stroke. [Research Support, U.S. Gov’t, P.H.S.]. 1981;12(2 Pt 2 Suppl 1):I13–44. [PubMed] [Google Scholar]
38. Pun VC, Hart JE, Kabrhel C, Camargo CA Jr., Baccarelli AA, Laden F Prospective Study of Ambient Particulate Matter Exposure and Risk of Pulmonary Embolism in the Nurses’ Health Study Cohort. Environmental health perspectives. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2015;123(12):1265–70. [PMC free article] [PubMed] [Google Scholar]
39. Kabrhel C, Varraso R, Goldhaber SZ, Rimm E, Camargo CA, Jr. Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ. [Research Support, N.I.H., Extramural]. 2011;343:d3867. [PMC free article] [PubMed] [Google Scholar]
40. Poole EM, Lin WT, Kvaskoff M, De Vivo I, Terry KL, Missmer SA. Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses. Cancer causes & control : CCC. 2017;28(5):437–45. [PMC free article] [PubMed] [Google Scholar]
41. Puckett CD. The Educational Annotation of ICD-9-CM; Diseases and Procedures Tabular Lists. Reno, NV; 1986. [Google Scholar]
42. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. American journal of epidemiology. [Research Support, U.S. Gov’t, P.H.S.]. 1994;140(11):1016–9. [PubMed] [Google Scholar]
43. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. American journal of epidemiology. [Research Support, U.S. Gov’t, P.H.S.]. 1984;119(5):837–9. [PubMed] [Google Scholar]
44. Zahl PH, Jorgensen KJ, Maehlen J, Gotzsche PC. Biases in estimates of overdetection due to mammography screening. The Lancet Oncology. [Comment Letter]. 2008;9(3):199–201; author reply −2. [PubMed] [Google Scholar]
45. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. Jama. [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Intramural]. 2013;310(13):1353–68. [PMC free article] [PubMed] [Google Scholar]
46. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstetrics and gynecology. [Research Support, Non-U.S. Gov’t]. 2006;108(6):1354–60. [PubMed] [Google Scholar]
47. Pinkerton JV, Kaunitz AM, Manson JE. Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. Menopause. 2017;24(12):1329–32. [PubMed] [Google Scholar]
48. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2009;16(1):30–6. [PubMed] [Google Scholar]
49. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane database of systematic reviews. [Meta-Analysis Review] 2006(4):CD001500. [PubMed] [Google Scholar]
50. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S. Use of low potency estrogens does not reduce the risk of hip fracture. Bone. [Research Support, Non-U.S. Gov’t]. 2002;30(4):613–8. [PubMed] [Google Scholar]
51. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. American journal of obstetrics and gynecology. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 1997;177(1):115–9. [PubMed] [Google Scholar]